Cancer has continued to have an adverse effect on many families. According to official data, cancer cases continue to increase. In addition, therapies/ treatment for the disease remain elusive. However, some experts have been conducting in depth research on how to develop viable cancer drugs. One of these researchers is Clay Siegall, a genetic expert. For the better part of his career, Siegall has been developing cancer therapies.
In 1997, Siegall founded Seattle Genetics. The scientist is the CEO of the corporation. Over the years, he has been using his experience to find a drug that cure or improve the lives of cancer patients. Clay has been a proponent of the antibody-drug conjugates (ADCs) technology. The company’s stock prices rose by more than 300 percent in five years owing to the success of this method.
Siegall has had an impressive career. He has worked for some of the best research institutions and pharmaceutical companies in the United States. They include Bristol-Myers Squibb Pharmaceutical Research Institute and National Cancer Institute. In the former company, he worked as a senior research investigator. In the latter, Clay worked as a Staff Fellow and Biotechnology Fellow. Clay holds a doctorate degree in genetics from the George Washington University.
Seattle Genetics has greatly benefited from the visionary leadership of Dr. Siegall. He has been seeking funds for the company, a move that has enabled it to raise adequate funds for its operations and development of cancer therapies. Clay played an instrumental role in commercializing its first ADCs therapy. The drug, ADCETRIS, is sold in over 60 countries. FDA approved it in 2011. Seattle Genetics has also been able to generate revenues from licensing its technology to other companies that engage in developing cancer therapies. In total, Clay has helped the company to generate more than $1.2 billion in funding.
Siegall is not slowing down. The scientist continues to research heavily on cancer therapies. His hard work has helped him to make new discoveries about cancer. Clay has 15 patents. Dr. Siegall is also the author of several scientific papers, which are published by various medical journals. He has at least 70 peer-reviewed publications. Recently, the Alumnus of University of Maryland honored the scientist for his contribution to cancer and cancer therapy research.